Solid Tumors

Ewing treatment protocols			
Study	**Clinical trial name**	**Phase/type**	**Age**
Aflac ST1502 CHOANOME II	AflacST1502: A Phase II Study of Sirolimus in Combination with Metronomic Chemotherapy in Children with Recurrent and/or Refractory Solid and CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02574728	II	>12 mo to ≤30 yr
COG ADVL1622	ADVL1622, Phase 2 Trial of XL184 (Cabozantinib), an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors https://clinicaltrials.gov/ct2/show/NCT02867592	II	≥2 to ≤30 yr except ≤18 yr for MTC, RCC, and HCC
COG ADVL1722	A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) https://clinicaltrials.gov/ct2/show/NCT03441360	II	≥12 mo to <18 yr
COG ADVL1823	ADVL1823, Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias https://clinicaltrials.gov/ct2/show/NCT03834961	II	≤30 yr
COG APEC1621A[REQ]	APEC1621A: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions https://clinicaltrials.gov/ct2/show/NCT03213704	II	≥12 mo to ≤21 yr
COG APEC1621B[REQ]	APEC1621B: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Relapsed Pediatric Solid Tumors Harboring FGFR1/2/3/4 Alterations https://clinicaltrials.gov/ct2/show/NCT03210714	II	≥12 mo to ≤21 yr
COG APEC1621C[REQ]	APEC1621C: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex https://clinicaltrials.gov/ct2/show/NCT03213665	II	≥12 mo to ≤21 yr
COG APEC1621D[REQ]	APEC1621D NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03213678	II	≥12 mo to ≤21 yr

COG APEC1621E[REQ]	APEC1621E NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Selumetinib in Patients with Tumors Harboring Activating MAPK Pathway Mutations https://clinicaltrials.gov/ct2/show/NCT03213691	II	≥12 mo to ≤21 yr
COG APEC1621F[REQ]	APEC1621F NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations https://clinicaltrials.gov/ct2/show/NCT03213652	II	≥12 mo to ≤21 yr

COG APEC1621G[REQ]	APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Actionable BRAF V600 Mutations https://clinicaltrials.gov/ct2/show/NCT03220035	II	≥12 mo to ≤21 yr
COG APEC1621H[REQ]	APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes https://clinicaltrials.gov/ct2/show/NCT03233204	II	≥12 mo to ≤21 yr
COG APEC1621I[REQ]	APEC1621I NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes https://clinicaltrials.gov/ct2/show/NCT03526250	II	≥12 mo to ≤21 yr
COG ADVL1312	A Phase 1/2 Study of MK-1775 (AZD1775, IND# 121422) in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT02095132	I/II	>12 mo to ≤21 yr
COG ADVL1412	A Phase 1/2 Study of Nivolumab (IND# 124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab https://clinicaltrials.gov/ct2/show/NCT02304458	I/II	Part B4 Ewing/ Periph PNET: ≥12 mo to ≤30 yr
COG ADVL1614	ADVL1614: A Phase 1/2 Study of VX15/2503 (IND# 136181) in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors Age: Part A: ≥12 mo to ≤21 yr Part B: Osteo-sarcoma—≥22 to ≤30 yr until Part A is complete. Part B expands to ≥12 mo to ≤30 yr once Part A is complete. https://clinicaltrials.gov/ct2/show/NCT03320330	I/II	See second column
COG ADVL1721	A Non-randomized, Open-label, Multi-center, Phase I/II Study of PI3K Inhibitor Copanlisib in Pediatric Patients with Relapsed/ Refractory Solid Tumors or Lymphoma https://clinicaltrials.gov/ct2/show/NCT03458728	I/II	≥6 mo to ≤21 yr

Ignyta RXDX-101-03	A Phase I/Ib, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02650401	I/Ib	≥2 to <22 yr
LOXO-EXT-17005	LOXO-EXT-17005: A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers https://clinicaltrials.gov/ct2/show/NCT03215511	I/II	≥1 mo
COG ADVL1414	ADVL1414, A Phase 1 Study of Selinexor (KPT-330, IND# 125052), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02323880?term=ADVL1414&cntry=US&state=US%3AGA&rank=1	I	≥12 mo to ≤21 yr
COG ADVL1514	ADVL1514, A Phase 1 Study of ABI-009 (Nab-Rapamycin) (IND# 133537) in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan https://clinicaltrials.gov/ct2/show/NCT02975882	I	≥12 mo to ≤21 yr
COG ADVL1615	ADVL1615, A Phase 1 Study of Pevonedistat (MLN4924 IND# 136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03323034	I	Part A1: ≥12 mo to ≤21 yr Part A2: ≥6 mo to <12 mo
COG ADVL1921	Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance®) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03709680	I	≥2 to <21 yr
AflacST1501	Aflac ST1501, A Phase I Study of Abemaciclib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and in Children with Recurrent and Refractory Solid Tumors Including Malignant Brain Tumors https://clinicaltrials.gov/ct2/show/NCT02644460	I	≥2 to ≤25 yr
AflacST1603 GemAbrax	AflacST1603: A Phase 1 Study Using Nab-paclitaxel (Abraxane®) in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03507491	I	≥6 mo to ≤30 yr
AbbVie M13-833	A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies https://clinicaltrials.gov/ct2/show/NCT03236857	I	<25 yr
Ewing biology, supportive treatment and non-therapeutic protocols			
AflacPM1702	Aflac Precision Medicine Program (APMP) Study	Non-therapeutic	<30 yr

COG APEC14B1	APEC14B1: The Project:Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study https://clinicaltrials.gov/ct2/show/NCT02402244	Non-therapeutic	≤25 yr
COG APEC1621SC	APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol https://clinicaltrials.gov/ct2/show/NCT03155620	NA	≥12 mo to ≤21 yr
COG ALTE03N1	Key Adverse Events after Childhood Cancer (cardiac, stroke, secondary malign)/closed to AVN patients as of 11-26-08 https://clinicaltrials.gov/ct2/show/NCT00082745	Non-therapeutic	≤21 yr at dx
COG ALTE05N1	Umbrella Long-Term Follow-Up Protocol https://clinicaltrials.gov/ct2/show/NCT00736749	Non-therapeutic	Any age
DFHCC ctDNA	Evaluation of ctDNA as a Prognostic Biomarker for Patients with Newly Diagnosed Localized Ewing Sarcoma or Osteosarcoma	Non-therapeutic	≥12 mo
Neuroblastoma treatment protocols			
COG ANBL1232[REQ]	Utilizing Response- and Biology-based Risk Factors to Guide Therapy in Patients with Non-high Risk Neuroblastoma https://clinicaltrials.gov/ct2/show/NCT02176967	III	<12 mo at diag with INRG Stage L1 <18 mo at diag with INRG Stage L2 or Stage Ms nbl
COG ANBL1531	ANBL1531: A Phase 3 Study of ^{131}I-Metaiodobenzylguanidine (^{131}-I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-risk Neuroblastoma (NBL) (IND# 134379) https://clinicaltrials.gov/ct2/show/NCT03126916	III	≥365 days to ≤30 yr
Aflac ST1502 CHOANOME II	AflacST1502: A Phase II Study of Sirolimus in Combination with Metronomic Chemotherapy in Children with Recurrent and/or Refractory Solid and CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02574728	II	>12 mo to ≤30 yr
COG ADVL1823	ADVL1823, Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias https://clinicaltrials.gov/ct2/show/NCT03834961	II	≤30 yr
COG ANBL1821	ANBL1821: A Phase 2 Randomized Study of Irinotecan/ Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma https://clinicaltrials.gov/ct2/show/NCT03794349	II	≥1 yr
COG APEC1621A[REQ]	APEC1621A: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions https://clinicaltrials.gov/ct2/show/NCT03213704	II	≥12 mo to ≤21 yr

COG APEC1621B[REQ]	APEC1621B: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Relapsed Pediatric Solid Tumors Harboring FGFR1/2/3/4 Alterations https://clinicaltrials.gov/ct2/show/NCT03210714	II	≥12 mo to ≤21 yr
COG APEC1621C[REQ]	APEC1621C: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex https://clinicaltrials.gov/ct2/show/NCT03213665	II	≥12 mo to ≤21 yr
COG APEC1621D[REQ]	APEC1621D NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03213678	II	≥12 mo to ≤21 yr
COG APEC1621E[REQ]	APEC1621E NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Selumetinib in Patients with Tumors Harboring Activating MAPK Pathway Mutations https://clinicaltrials.gov/ct2/show/NCT03213691	II	≥12 mo to ≤21 yr
COG APEC1621F[REQ]	APEC1621F NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations https://clinicaltrials.gov/ct2/show/NCT03213652	II	≥12 mo to ≤21 yr
COG APEC1621G[REQ]	APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Actionable BRAF V600 Mutations https://clinicaltrials.gov/ct2/show/NCT03220035	II	≥12 mo to ≤21 yr
COG APEC1621H[REQ]	APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes https://clinicaltrials.gov/ct2/show/NCT03233204	II	≥12 mo to ≤21 yr
COG APEC1621I[REQ]	APEC1621I NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes https://clinicaltrials.gov/ct2/show/NCT03526250	II	≥12 mo to ≤21 yr
COG ADVL1614	ADVL1614: A Phase 1/2 Study of VX15/2503 (IND# 136181) in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors Age: Part A: ≥12 mo to ≤21 yr Part B: Osteo-sarcoma—≥22 to ≤30 yr until Part A is complete. Part B expands to ≥12 mo to ≤30	I/II	See second column

	yr once Part A is complete. https://clinicaltrials.gov/ct2/show/NCT03320330		
COG ADVL1721	A Non-randomized, Open-label, Multi-center, Phase I/II Study of PI3K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refractory Solid Tumors or Lymphoma https://clinicaltrials.gov/ct2/show/NCT03458728	I/II	≥6 mo to ≤21 yr
Ignyta RXDX-101-03	A Phase I/Ib, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02650401	I/Ib	≥2 to <22 yr
LOXO-EXT-17005	LOXO-EXT-17005: A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers https://clinicaltrials.gov/ct2/show/NCT03215511	I/II	≥1 mo
NANT 2013-01	NANT 2013-01: A Phase I Dose Escalation Study of Autologous Expanded Natural Killer (NK) Cells for Immunotherapy of Relapsed Refractory Neuroblastoma with Dinutuximab +/- Lenalidomide https://clinicaltrials.gov/ct2/show/NCT02573896	I	≤30 yr
NANT 2015-02[REQ]	NANT 2015-02: Phase 1 Study of Lorlatinib (PF-06463922), an Oral Small Molecule Inhibitor of ALK/ROS1, for Patients with ALK-driven Relapsed or Refractory Neuroblastoma https://clinicaltrials.gov/ct2/show/NCT03107988	I	≥12 mo
NANT 2017-01 [REQ]	NANT 2017-01: A Phase I Study of ^{131}I-MIBG with Dinutuximab for Relapsed/Refractory Neuroblastoma (IND# 137554) https://clinicaltrials.gov/ct2/show/NCT03332667	I	≥1 to <30 yr
AflacST1501	Aflac ST1501, A Phase I Study of Abemaciclib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and in Children with Recurrent and Refractory Solid Tumors Including Malignant Brain Tumors https://clinicaltrials.gov/ct2/show/NCT02644460	I	≥2 to ≤25 yr
AflacST1603 GemAbrax	AflacST1603: A Phase 1 Study Using Nab-paclitaxel (Abraxane®) in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03507491	I	≥6 mo to ≤30 yr
AbbVie M13-833	A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies https://clinicaltrials.gov/ct2/show/NCT03236857	I	<25 yr
COG ADVL1615	ADVL1615, A Phase 1 Study of Pevonedistat (MLN4924 IND# 136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03323034	I	Part A1: ≥12 mo to ≤21 yr Part A2: ≥6 mo to

			<12 mo
COG ADVL1921	Phase 1 Study to Evaluate the Safety and Phrmacokinetics of Palbociclib (Ibrance®) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03709680	I	≥2 to <21 yr
MIBG Access	An Open Label, Expanded Access Protocol Using ^{131}I-Metaiodobenzylguanidine (^{131}I-MIBG) Therapy in Patients with Refractory Neuroblastoma, Pheochromocytoma, or Paragangioma	Access to MIBG therapy	≥12 mo
Neuroblastoma biology, supportive treatment and non-therapeutic protocols			
AflacPM1702	Aflac Precision Medicine Program (APMP) Study	Non-therapeutic	<30 yr
COG APEC14B1	APEC14B1: The Project:Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study https://clinicaltrials.gov/ct2/show/NCT02402244	Non-therapeutic	≤25 yr
COG APEC1621SC	APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol https://clinicaltrials.gov/ct2/show/NCT03155620	NA	≥12 mo to ≤21 yr
COG ANBL00B1	Neuroblastoma Biology Studies	Biology	<31 yr
NANT 2004-05	Neuroblastoma Biology Study (Any patient with high risk neuroblastoma who is not enrolled on a COG frontline therapeutic study is eligible if undergoing a disease evaluation.)	Biology	≥31 days
NANT 2015-01	Neuroblastoma Precision Trial	Biology	≥1 to ≤30 yr
COG ALTE03N1	Key Adverse Events after Childhood Cancer (cardiac, stroke, secondary malign)/(closed to AVN patients as of 11-26-08) https://clinicaltrials.gov/ct2/show/NCT00082745	Non-therapeutic	≤21 yr at dx
COG ALTE05N1	Umbrella Long-Term Follow-Up Protocol https://clinicaltrials.gov/ct2/show/NCT00736749	Non-therapeutic	Any age
COG ALTE15N2	ALTE15N2: LEAHRN (Late Effects After High-Risk Neuroblastoma) Study https://clinicaltrials.gov/ct2/show/NCT03057626	Non-therapeutic	≥5 yr

AflacST17B1	AflacST17B1: Immunophenotyping and Cytokine Profiling of Patients Receiving Therapeutic 131I-MIBG for Relapsed/ Refractory Neuroblastoma	Biology	≥1 to ≤30 yr
Osteosarcoma treatment protocols			
COG ADVL1622	ADVL1622, Phase 2 Trial of XL184 (Cabozantinib), an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors https://clinicaltrials.gov/ct2/show/NCT02867592	II	≥2 to ≤30 yr except ≤18 yr for MTC, RCC, and HCC
COG ADVL1823	ADVL1823, Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias https://clinicaltrials.gov/ct2/show/NCT03834961	II	≤30 yr
COG APEC1621A[REQ]	APEC1621A: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions https://clinicaltrials.gov/ct2/show/NCT03213704	II	≥12 mo to ≤21 yr
COG APEC1621B[REQ]	APEC1621B: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Relapsed Pediatric Solid Tumors Harboring FGFR1/2/3/4 Alterations https://clinicaltrials.gov/ct2/show/NCT03210714	II	≥12 mo to ≤21 yr
COG APEC1621C[REQ]	APEC1621C: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex https://clinicaltrials.gov/ct2/show/NCT03213665	II	≥12 mo to ≤21 yr
COG APEC1621D[REQ]	APEC1621D NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03213678	II	≥12 mo to ≤21 yr
COG APEC1621E[REQ]	APEC1621E NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Selumetinib in Patients with Tumors Harboring Activating MAPK Pathway Mutations https://clinicaltrials.gov/ct2/show/NCT03213691	II	≥12 mo to ≤21 yr
COG APEC1621F[REQ]	APEC1621F NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations https://clinicaltrials.gov/ct2/show/NCT03213652	II	≥12 mo to ≤21 yr
COG APEC1621G[REQ]	APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Vemurafenib in	II	≥12 mo to ≤21 yr

	Patients with Tumors Harboring Actionable BRAF V600 Mutations https://clinicaltrials.gov/ct2/show/NCT03220035		

COG APEC1621H[REQ]	APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes https://clinicaltrials.gov/ct2/show/NCT03233204	II	≥12 mo to ≤21 yr
COG APEC1621I[REQ]	APEC1621I NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes https://clinicaltrials.gov/ct2/show/NCT03526250	II	≥12 mo to ≤21 yr
Aflac ST1502 CHOANOME II	AflacST1502: A Phase II Study of Sirolimus in Combination with Metronomic Chemotherapy in Children with Recurrent and/or Refractory Solid and CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02574728	II	>12 mo to ≤30 yr
COG ADVL1412	A Phase 1/2 Study of Nivolumab (IND# 124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab https://clinicaltrials.gov/ct2/show/NCT02304458	I/II	Part B2 Osteo-sarcoma: ≥12 mo to ≤30 yr
COG ADVL1614	ADVL1614: A Phase 1/2 Study of VX15/2503 (IND# 136181) in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors Age: Part A: ≥12 mo to ≤21 yr Part B: Osteo-sarcoma—≥22 to ≤30 yr until Part A is complete. Part B expands to ≥12 mo to ≤30 yr once Part A is complete. https://clinicaltrials.gov/ct2/show/NCT03320330	I/II	See second column
COG ADVL1721	A Non-randomized, Open-label, Multi-center, Phase I/II Study of PI3K Inhibitor Copanlisib in Pediatric Patients with Relapsed/ Refractory Solid Tumors or Lymphoma https://clinicaltrials.gov/ct2/show/NCT03458728	I/II	≥6 mo to ≤21 yr
Ignyta RXDX-101-03	A Phase I/Ib, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02650401	I/Ib	≥2 to <22 yr
LOXO-EXT-17005	LOXO-EXT-17005: A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers https://clinicaltrials.gov/ct2/show/NCT03215511	I/II	≥1 mo
COG ADVL1414	ADVL1414, A Phase 1 Study of Selinexor (KPT-330, IND# 125052), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02323880?term=ADVL1414&cntry=US&state=US%3AGA&rank=1	I	≥12 mo to ≤21 yr

COG ADVL1514	ADVL1514, A Phase 1 Study of ABI-009 (Nab-Rapamycin) (IND# 133537) in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan https://clinicaltrials.gov/ct2/show/NCT02975882	I	≥12 mo to ≤21 yr

COG ADVL1615	ADVL1615, A Phase 1 Study of Pevonedistat (MLN4924 IND# 136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03323034	I	Part A1: ≥12 mo to ≤21 yr Part A2: ≥6 mo to <12 mo
COG ADVL1921	Phase 1 Study to Evaluate the Safety and Phrmacokinetics of Palbociclib (Ibrance®) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03709680	I	≥2 to <21 yr
AbbVie M13-833	A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies https://clinicaltrials.gov/ct2/show/NCT03236857	I	<25 yr
AflacST1501	Aflac ST1501, A Phase I Study of Abemaciclib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and in Children with Recurrent and Refractory Solid Tumors Including Malignant Brain Tumors https://clinicaltrials.gov/ct2/show/NCT02644460	I	≥2 to ≤25 yr
AflacST1603 GemAbrax	AflacST1603: A Phase 1 Study Using Nab-paclitaxel (Abraxane®) in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03507491	I	≥6 mo to ≤30 yr
Osteosarcoma biology, supportive treatment and non-therapeutic protocols			
AflacPM1702	Aflac Precision Medicine Program (APMP) Study	Non-therapeutic	<30 yr
COG APEC14B1	APEC14B1: The Project:Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study https://clinicaltrials.gov/ct2/show/NCT02402244	Non-therapeutic	≤25 yr
COG APEC1621SC	APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol https://clinicaltrials.gov/ct2/show/NCT03155620	NA	≥12 mo to ≤21 yr
COG ALTE03N1	Key Adverse Events after Childhood Cancer (cardiac, stroke, secondary malign)/(closed to AVN patients as of 11-26-08) https://clinicaltrials.gov/ct2/show/NCT00082745	Non-therapeutic	≤21 yr at dx

COG ALTE05N1	Umbrella Long-Term Follow-Up Protocol https://clinicaltrials.gov/ct2/show/NCT00736749	Non-therapeutic	Any age

DFHCC ctDNA	Evaluation of ctDNA as a Prognostic Biomarker for Patients with Newly Diagnosed Localized Ewing Sarcoma or Osteosarcoma	Non-therapeutic	≥12 mo
Retinoblastoma treatment protocols			
COG ADVL1823	ADVL1823, Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias https://clinicaltrials.gov/ct2/show/NCT03834961	II	≤30 yr
COG APEC1621A[RE Q]	APEC1621A: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions https://clinicaltrials.gov/ct2/show/NCT03213704	II	≥12 mo to ≤21 yr
COG APEC1621B[RE Q]	APEC1621B: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Relapsed Pediatric Solid Tumors Harboring FGFR1/2/3/4 Alterations https://clinicaltrials.gov/ct2/show/NCT03210714	II	≥12 mo to ≤21 yr
COG APEC1621C[RE Q]	APEC1621C: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex https://clinicaltrials.gov/ct2/show/NCT03213665	II	≥12 mo to ≤21 yr
COG APEC1621D[RE Q]	APEC1621D NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03213678	II	≥12 mo to ≤21 yr
COG APEC1621E[RE Q]	APEC1621E NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Selumetinib in Patients with Tumors Harboring Activating MAPK Pathway Mutations https://clinicaltrials.gov/ct2/show/NCT03213691	II	≥12 mo to ≤21 yr
COG APEC1621F[RE Q]	APEC1621F NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations https://clinicaltrials.gov/ct2/show/NCT03213652	II	≥12 mo to ≤21 yr
COG APEC1621G[R EQ]	APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Actionable BRAF V600 Mutations https://clinicaltrials.gov/ct2/show/NCT03220035	II	≥12 mo to ≤21 yr

COG APEC1621H[RE Q]	APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes https://clinicaltrials.gov/ct2/show/NCT03233204	II	≥12 mo to ≤21 yr
COG APEC1621I[RE Q]	APEC1621I NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes https://clinicaltrials.gov/ct2/show/NCT03526250	II	≥12 mo to ≤21 yr
Aflac ST1502 CHOANOME II	AflacST1502: A Phase II Study of Sirolimus in Combination with Metronomic Chemotherapy in Children with Recurrent and/or Refractory Solid and CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02574728	II	>12 mo to ≤30 yr
COG ADVL1614	ADVL1614: A Phase 1/2 Study of VX15/2503 (IND# 136181) in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors Age: Part A: ≥12 mo to ≤21 yr Part B: Osteo-sarcoma—≥22 to ≤30 yr until Part A is complete. Part B expands to ≥12 mo to ≤30 yr once Part A is complete. https://clinicaltrials.gov/ct2/show/NCT03320330	I/II	See second column
COG ADVL1721	A Non-randomized, Open-label, Multi-center, Phase I/II Study of PI3K Inhibitor Copanlisib in Pediatric Patients with Relapsed/ Refractory Solid Tumors or Lymphoma https://clinicaltrials.gov/ct2/show/NCT03458728	I/II	≥6 mo to ≤21 yr
Ignyta RXDX-101-03	A Phase I/Ib, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02650401	I/Ib	≥2 to <22 yr
LOXO-EXT-17005	LOXO-EXT-17005: A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers https://clinicaltrials.gov/ct2/show/NCT03215511	I/II	≥1 mo
COG ADVL1921	Phase 1 Study to Evaluate the Safety and Phrmacokinetics of Palbociclib (Ibrance®) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03709680	I	≥2 to <21 yr
AflacST1501	Aflac ST1501, A Phase I Study of Abemaciclib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and in Children with Recurrent and Refractory Solid Tumors Including Malignant Brain Tumors https://clinicaltrials.gov/ct2/show/NCT02644460	I	≥2 to ≤25 yr

AflacST1603 GemAbrax	AflacST1603: A Phase 1 Study Using Nab-paclitaxel (Abraxane®) in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03507491	I	≥6 mo to ≤30 yr
AbbVie M13-833	A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies https://clinicaltrials.gov/ct2/show/NCT03236857	I	<25 yr

Retinoblastoma biology, supportive treatment and non-therapeutic protocols			
AflacPM1702	Aflac Precision Medicine Program (APMP) Study	Non-therapeutic	<30 yr
COG APEC14B1	APEC14B1: The Project:Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study https://clinicaltrials.gov/ct2/show/NCT02402244	Non-therapeutic	≤25 yr
COG APEC1621SC	APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol https://clinicaltrials.gov/ct2/show/NCT03155620	NA	≥12 mo to ≤21 yr
COG ALTE05N1	Umbrella Long-Term Follow-Up Protocol https://clinicaltrials.gov/ct2/show/NCT00736749	Non-therapeutic	Any age
Rhabdo and non-rhabdo soft tissue sarcoma treatment protocols			
COG ARST1431	A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) https://clinicaltrials.gov/ct2/show/NCT02567435	III	Feasibility Phase <21 yr Efficacy Phase ≤40 yr
Aflac ST1502 CHOANOME II	AflacST1502: A Phase II Study of Sirolimus in Combination with Metronomic Chemotherapy in Children with Recurrent and/or Refractory Solid and CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02574728	II	>12 mo to ≤30 yr
COG ADVL1722	A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) https://clinicaltrials.gov/ct2/show/NCT03441360	II	≥12 mo to <18 yr
COG ADVL1823	ADVL1823, Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias https://clinicaltrials.gov/ct2/show/NCT03834961	II	≤30 yr

COG APEC1621A[RE Q]	APEC1621A: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions https://clinicaltrials.gov/ct2/show/NCT03213704	II	≥12 mo to ≤21 yr
COG APEC1621B[RE Q]	APEC1621B: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Relapsed Pediatric Solid Tumors Harboring FGFR1/2/3/4 Alterations https://clinicaltrials.gov/ct2/show/NCT03210714	II	≥12 mo to ≤21 yr

COG APEC1621C[RE Q]	APEC1621C: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex https://clinicaltrials.gov/ct2/show/NCT03213665	II	≥12 mo to ≤21 yr
COG APEC1621D[RE Q]	APEC1621D NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03213678	II	≥12 mo to ≤21 yr
COG APEC1621E[RE Q]	APEC1621E NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Selumetinib in Patients with Tumors Harboring Activating MAPK Pathway Mutations https://clinicaltrials.gov/ct2/show/NCT03213691	II	≥12 mo to ≤21 yr
COG APEC1621F[RE Q]	APEC1621F NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations https://clinicaltrials.gov/ct2/show/NCT03213652	II	≥12 mo to ≤21 yr
COG APEC1621G[R EQ]	APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Actionable BRAF V600 Mutations https://clinicaltrials.gov/ct2/show/NCT03220035	II	≥12 mo to ≤21 yr
COG APEC1621H[RE Q]	APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes https://clinicaltrials.gov/ct2/show/NCT03233204	II	≥12 mo to ≤21 yr
COG APEC1621I[RE Q]	APEC1621I NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes https://clinicaltrials.gov/ct2/show/NCT03526250	II	≥12 mo to ≤21 yr
COG ADVL1614	ADVL1614: A Phase 1/2 Study of VX15/2503 (IND# 136181) in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors Age: Part A: ≥12 mo to ≤21 yr	I/II	See second column

	Part B: Osteo-sarcoma—≥22 to ≤30 yr until Part A is complete. Part B expands to ≥12 mo to ≤30 yr once Part A is complete. https://clinicaltrials.gov/ct2/show/NCT03320330		
COG ADVL1721	A Non-randomized, Open-label, Multi-center, Phase I/II Study of PI3K Inhibitor Copanlisib in Pediatric Patients with Relapsed/ Refractory Solid Tumors or Lymphoma https://clinicaltrials.gov/ct2/show/NCT03458728	I/II	≥6 mo to ≤21 yr
Ignyta RXDX-101-03	A Phase I/Ib, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02650401	I/Ib	≥2 to <22 yr
LOXO-EXT-17005	LOXO-EXT-17005: A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers https://clinicaltrials.gov/ct2/show/NCT03215511	I/II	≥1 mo

COG ADVL1615	ADVL1615, A Phase 1 Study of Pevonedistat (MLN4924 IND# 136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03323034	I	Part A1: ≥12 mo to ≤21 yr Part A2: ≥6 mo to <12 mo
COG ADVL1921	Phase 1 Study to Evaluate the Safety and Phrmacokinetics of Palbociclib (Ibrance®) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03709680	I	≥2 to <21 yr
AflacST1501	Aflac ST1501, A Phase I Study of Abemaciclib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and in Children with Recurrent and Refractory Solid Tumors Including Malignant Brain Tumors https://clinicaltrials.gov/ct2/show/NCT02644460	I	≥2 to ≤25 yr
AflacST1603 GemAbrax	AflacST1603: A Phase 1 Study Using Nab-paclitaxel (Abraxane®) in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03507491	I	≥6 mo to ≤30 yr
AbbVie M13-833	A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies https://clinicaltrials.gov/ct2/show/NCT03236857	I	<25 yr
Rhabdo and non-rhabdo soft tissue sarcoma biology, supportive treatment and non-therapeutic protocols			

AflacPM1702	Aflac Precision Medicine Program (APMP) Study	Non-therapeutic	<30 yr
COG APEC14B1	APEC14B1: The Project:Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study https://clinicaltrials.gov/ct2/show/NCT02402244	Non-therapeutic	≤25 yr
COG APEC1621SC	APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol https://clinicaltrials.gov/ct2/show/NCT03155620	NA	≥12 mo to ≤21 yr
COG ALTE03N1	Key Adverse Events after Childhood Cancer (cardiac, stroke, secondary malign)/closed to AVN patients as of 11-26-08 https://clinicaltrials.gov/ct2/show/NCT00082745	Non-therapeutic	≤21 yr at dx
COG ALTE05N1	Umbrella Long-Term Follow-Up Protocol https://clinicaltrials.gov/ct2/show/NCT00736749	Non-therapeutic	Any age

Wilms treatment protocols			
Aflac ST1502 CHOANOME II	AflacST1502: A Phase II Study of Sirolimus in Combination with Metronomic Chemotherapy in Children with Recurrent and/or Refractory Solid and CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02574728	II	>12 mo to ≤30 yr
COG ADVL1622	ADVL1622, Phase 2 Trial of XL184 (Cabozantinib), an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors https://clinicaltrials.gov/ct2/show/NCT02867592	II	≥2 to ≤30 yr except ≤18 yr for MTC, RCC, and HCC
COG ADVL1823	ADVL1823, Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias https://clinicaltrials.gov/ct2/show/NCT03834961	II	≤30 yr
COG APEC1621A[REQ]	APEC1621A: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions https://clinicaltrials.gov/ct2/show/NCT03213704	II	≥12 mo to ≤21 yr
COG APEC1621B[REQ]	APEC1621B: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Relapsed Pediatric Solid Tumors Harboring FGFR1/2/3/4 Alterations https://clinicaltrials.gov/ct2/show/NCT03210714	II	≥12 mo to ≤21 yr
COG APEC1621C[REQ]	APEC1621C: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex	II	≥12 mo to ≤21 yr

	https://clinicaltrials.gov/ct2/show/NCT03213665		
COG APEC1621D[REQ]	APEC1621D NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03213678	II	≥12 mo to ≤21 yr
COG APEC1621E[REQ]	APEC1621E NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Selumetinib in Patients with Tumors Harboring Activating MAPK Pathway Mutations https://clinicaltrials.gov/ct2/show/NCT03213691	II	≥12 mo to ≤21 yr
COG APEC1621F[REQ]	APEC1621F NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations https://clinicaltrials.gov/ct2/show/NCT03213652	II	≥12 mo to ≤21 yr
COG APEC1621G[REQ]	APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Actionable BRAF V600 Mutations https://clinicaltrials.gov/ct2/show/NCT03220035	II	≥12 mo to ≤21 yr
COG APEC1621H[REQ]	APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes https://clinicaltrials.gov/ct2/show/NCT03233204	II	≥12 mo to ≤21 yr
COG APEC1621I[REQ]	APEC1621I NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes https://clinicaltrials.gov/ct2/show/NCT03526250	II	≥12 mo to ≤21 yr
COG AREN1721	A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFR/Translocation Renal Cell Cancinoma (tRCC) Across All Age Groups https://clinicaltrials.gov/ct2/show/NCT03595124	II	≥12 mo
COG ADVL1312	A Phase 1/2 Study of MK-1775 (AZD1775, IND# 121422) in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT02095132	I/II	>12 mo to ≤21 yr
COG ADVL1412	A Phase 1/2 Study of Nivolumab (IND# 124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab https://clinicaltrials.gov/ct2/show/NCT02304458	I/II	Parts A&C: ≥12 mo to <18 yr

COG ADVL1614	ADVL1614: A Phase 1/2 Study of VX15/2503 (IND# 136181) in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors Age: Part A: ≥12 mo to ≤21 yr Part B: Osteo-sarcoma—≥22 to ≤30 yr until Part A is complete. Part B expands to ≥12 mo to ≤30 yr once Part A is complete. https://clinicaltrials.gov/ct2/show/NCT03320330	I/II	See second column
COG ADVL1721	A Non-randomized, Open-label, Multi-center, Phase I/II Study of PI3K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refractory Solid Tumors or Lymphoma https://clinicaltrials.gov/ct2/show/NCT03458728	I/II	≥6 mo to ≤21 yr
Ignyta RXDX-101-03	A Phase I/Ib, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02650401	I/Ib	≥2 to <22 yr
LOXO-EXT-17005	LOXO-EXT-17005: A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers https://clinicaltrials.gov/ct2/show/NCT03215511	I/II	≥1 mo
COG ADVL1414	ADVL1414, A Phase 1 Study of Selinexor (KPT-330, IND# 125052), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02323880	I	≥12 mo to ≤21 yr
COG ADVL1514	ADVL1514, A Phase 1 Study of ABI-009 (Nab-Rapamycin) (IND# 133537) in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan https://clinicaltrials.gov/ct2/show/NCT02975882	I	≥12 mo to ≤21 yr

COG ADVL1615	ADVL1615, A Phase 1 Study of Pevonedistat (MLN4924 IND# 136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03323034	I	Part A1: ≥12 mo to ≤21 yr Part A2: ≥6 mo to <12 mo
COG ADVL1921	Phase 1 Study to Evaluate the Safety and Phrmacokinetics of Palbociclib (Ibrance®) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03709680	I	≥2 to <21 yr
AflacST1501	Aflac ST1501, A Phase I Study of Abemaciclib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and in Children with Recurrent and Refractory Solid Tumors Including Malignant Brain Tumors https://clinicaltrials.gov/ct2/show/NCT02644460	I	≥2 to ≤25 yr

AflacST1603 GemAbrax	AflacST1603: A Phase 1 Study Using Nab-paclitaxel (Abraxane®) in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03507491	I	≥6 mo to ≤30 yr
AbbVie M13-833	A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies https://clinicaltrials.gov/ct2/show/NCT03236857	I	<25 yr
Wilms biology, supportive treatment and non-therapeutic protocols			
AflacPM1702	Aflac Precision Medicine Program (APMP) Study	Non-therapeutic	<30 yr
COG APEC14B1	APEC14B1: The Project:Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study https://clinicaltrials.gov/ct2/show/NCT02402244	Non-therapeutic	≤25 yr
COG APEC1621SC	APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol https://clinicaltrials.gov/ct2/show/NCT03155620	NA	≥12 mo to ≤21 yr
COG AREN03B2[REQ]	Renal Tumors Classification, Biology, and Banking Study	Biology	<30 yr
COG ALTE05N1	Umbrella Long-Term Follow-Up Protocol https://clinicaltrials.gov/ct2/show/NCT00736749	Non-therapeutic	Any age
Other solid tumor and rare tumor treatment protocols			
COG AGCT1531	AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors https://clinicaltrials.gov/ct2/show/NCT03067181	III	Low Risk: <50 yr Std Risk 1: <11 yr Std Risk 2: ≥11 to <25 yr
COG AGCT1532	Phase 3 Accelerated BEP Trial: A Randomised Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumors	III	≥11 to ≤45 yr
Alliance A031102	A Randomized Phase III Trial Comparing Conventional-dose Chemotherapy using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-dose Chemotherapy using Mobilizing Paclitaxel plus Ifosfamide followed by High-dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors	III	≥14 yr males only

	https://clinicaltrials.gov/ct2/show/NCT02375204		
Aflac ST1502 CHOANOME II	AflacST1502: A Phase II Study of Sirolimus in Combination with Metronomic Chemotherapy in Children with Recurrent and/or Refractory Solid and CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02574728	II	>12 mo to ≤30 yr
COG ADVL1622	ADVL1622, Phase 2 Trial of XL184 (Cabozantinib), an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors https://clinicaltrials.gov/ct2/show/NCT02867592	II	≥2 to ≤30 yr except ≤18 yr for MTC, RCC, and HCC
COG ADVL1823	ADVL1823, Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias https://clinicaltrials.gov/ct2/show/NCT03834961	II	≤30 yr
COG APEC1621A[REQ]	APEC1621A: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions https://clinicaltrials.gov/ct2/show/NCT03213704	II	≥12 mo to ≤21 yr
COG APEC1621B[REQ]	APEC1621B: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Relapsed Pediatric Solid Tumors Harboring FGFR1/2/3/4 Alterations https://clinicaltrials.gov/ct2/show/NCT03210714	II	≥12 mo to ≤21 yr
COG APEC1621C[REQ]	APEC1621C: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex https://clinicaltrials.gov/ct2/show/NCT03213665	II	≥12 mo to ≤21 yr
COG APEC1621D[REQ]	APEC1621D NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03213678	II	≥12 mo to ≤21 yr
COG APEC1621E[REQ]	APEC1621E NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Selumetinib in Patients with Tumors Harboring Activating MAPK Pathway Mutations https://clinicaltrials.gov/ct2/show/NCT03213691	II	≥12 mo to ≤21 yr

COG APEC1621F[REQ]	APEC1621F NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations https://clinicaltrials.gov/ct2/show/NCT03213652	II	≥12 mo to ≤21 yr
COG APEC1621G[REQ]	APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Actionable BRAF V600 Mutations https://clinicaltrials.gov/ct2/show/NCT03220035	II	≥12 mo to ≤21 yr
COG APEC1621H[REQ]	APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes https://clinicaltrials.gov/ct2/show/NCT03233204	II	≥12 mo to ≤21 yr
COG APEC1621I[REQ]	APEC1621I NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes https://clinicaltrials.gov/ct2/show/NCT03526250	II	≥12 mo to ≤21 yr
LCH-IV (NACHO)	LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis https://clinicaltrials.gov/ct2/show/NCT02205762	II	≤18 yr
SIR-DA-1202	A Randomized Phase 2 Study of Vincristine versus Sirolimus to treat High Risk Kaposiform Hemangioendothelioma (KHE) https://clinicaltrials.gov/ct2/show/NCT02110069	II	≤31 yr
Ignyta RXDX-101-03	A Phase I/Ib, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02650401	I/Ib	≥2 to <22 yr
LOXO-EXT-17005	LOXO-EXT-17005: A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers https://clinicaltrials.gov/ct2/show/NCT03215511	I/II	≥1 mo
AflacST1501	Aflac ST1501, A Phase I Study of Abemaciclib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and in Children with Recurrent and Refractory Solid Tumors Including Malignant Brain Tumors https://clinicaltrials.gov/ct2/show/NCT02644460	I	≥2 to ≤25 yr

AflacST1603 GemAbrax	AflacST1603: A Phase 1 Study Using Nab-paclitaxel (Abraxane®) in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03507491	I	≥6 mo to ≤30 yr
EZH-102	A Phase I Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma https://clinicaltrials.gov/ct2/show/NCT02601937	I	≥6 mo to ≤21 yr
AbbVie M13-833	A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies https://clinicaltrials.gov/ct2/show/NCT03236857	I	<25 yr
Other solid tumor and rare tumor biology, supportive treatment and non-therapeutic protocols			
AflacPM1702	Aflac Precision Medicine Program (APMP) Study	Non-therapeutic	<30 yr
COG APEC14B1	APEC14B1: The Project:Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study https://clinicaltrials.gov/ct2/show/NCT02402244	Non-therapeutic	≤25 yr
COG APEC1621SC	APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol https://clinicaltrials.gov/ct2/show/NCT03155620	NA	≥12 mo to ≤21 yr
PPB DICER1	International Pleuropulmonary Blastoma Registry for PPB, *DICER1* and Associated Conditions	Registry	Any age
COG ALTE03N1	Key Adverse Events after Childhood Cancer (cardiac, stroke, secondary malign)/closed to AVN patients as of 11-26-08 https://clinicaltrials.gov/ct2/show/NCT00082745	Non-therapeutic	≤21 yr at dx
COG ALTE05N1	Umbrella Long-Term Follow-Up Protocol https://clinicaltrials.gov/ct2/show/NCT00736749	Non-therapeutic	Any age
QOL Thyroid	The Quality of Life in Children and Adolescents with Thyroid Cancer	Non-therapeutic	2 to 21 yr
NACHO BIO	NACHO-BIO: A Translational Biology Platform to Advance Understanding of Pathogenesis and Improve Outcomes for Patients with Histiocytic Disorders	Non-therapeutic	Any age